

	<b>Age (years)</b>	<b>Sex</b>
<b>CIP</b>	71.5 ± 3.2	25% Male
<b>AD</b>	30.0 ± 14.1	50% Male
<b>Control</b>	72.0 ± 2.1	50% Male

**Table S1. Demographics of human skin sample donors. Relates to Figure 5.**

Demographics of CIP (N = 4), AD (N = 4), and control skin (N = 4) donors. Age presented as mean ± standard deviation of each group.

GO Accession Number	Name	NES	FDR q-value
GO:0002682	regulation of immune system process	-8.77036	< 10 <sup>-5</sup>
GO:0002376	immune system process	-8.66961	< 10 <sup>-5</sup>
GO:0080134	regulation of response to stress	-8.02582	< 10 <sup>-5</sup>
GO:0050776	regulation of immune response	-7.8129	< 10 <sup>-5</sup>
GO:0022613	ribonucleoprotein complex biogenesis	-7.7964	< 10 <sup>-5</sup>
GO:0002684	positive regulation of immune system process	-7.77017	< 10 <sup>-5</sup>
GO:0006952	defense response	-7.49978	< 10 <sup>-5</sup>
GO:0044403	symbiosis, encompassing mutualism through parasitism	-7.30644	< 10 <sup>-5</sup>
GO:0050778	positive regulation of immune response	-7.20636	< 10 <sup>-5</sup>
GO:0044419	interspecies interaction between organisms	-7.18966	< 10 <sup>-5</sup>
GO:0042254	ribosome biogenesis	-7.11062	< 10 <sup>-5</sup>
GO:0031347	regulation of defense response	-7.10497	< 10 <sup>-5</sup>
GO:0048584	positive regulation of response to stimulus	-7.05507	< 10 <sup>-5</sup>
GO:0006396	RNA processing	-7.04048	< 10 <sup>-5</sup>
GO:0009607	response to biotic stimulus	-6.93027	< 10 <sup>-5</sup>
GO:0043604	amide biosynthetic process	-6.89239	< 10 <sup>-5</sup>
GO:0034660	ncRNA metabolic process	-6.8318	< 10 <sup>-5</sup>
GO:0006955	immune response	-6.73395	< 10 <sup>-5</sup>
GO:0002253	activation of immune response	-6.70878	< 10 <sup>-5</sup>
GO:0006518	peptide metabolic process	-6.6791	< 10 <sup>-5</sup>
GO:0016072	rRNA metabolic process	-6.56767	< 10 <sup>-5</sup>
GO:1901564	organonitrogen compound metabolic process	-6.55732	< 10 <sup>-5</sup>
GO:0019058	viral life cycle	-6.53858	< 10 <sup>-5</sup>
GO:0031349	positive regulation of defense response	-6.52802	< 10 <sup>-5</sup>
GO:0034470	ncRNA processing	-6.35599	< 10 <sup>-5</sup>
GO:1901566	organonitrogen compound biosynthetic process	-6.31783	< 10 <sup>-5</sup>
GO:0043603	cellular amide metabolic process	-6.24033	< 10 <sup>-5</sup>
GO:0061024	membrane organization	-6.19839	< 10 <sup>-5</sup>
GO:0032101	regulation of response to external stimulus	-6.11073	< 10 <sup>-5</sup>
GO:0045184	establishment of protein localization	-6.09473	< 10 <sup>-5</sup>
GO:0071310	cellular response to organic substance	-6.08981	< 10 <sup>-5</sup>
GO:0002218	activation of innate immune response	-6.07281	< 10 <sup>-5</sup>
GO:0034097	response to cytokine	-6.07209	< 10 <sup>-5</sup>
GO:0009057	macromolecule catabolic process	-6.07098	< 10 <sup>-5</sup>
GO:0045089	positive regulation of innate immune response	-6.04607	< 10 <sup>-5</sup>
GO:0051649	establishment of localization in cell	-6.03101	< 10 <sup>-5</sup>
GO:0007005	mitochondrion organization	-6.02195	< 10 <sup>-5</sup>
GO:0008104	protein localization	-6.0172	< 10 <sup>-5</sup>
GO:0045088	regulation of innate immune response	-5.9712	< 10 <sup>-5</sup>
GO:0065003	macromolecular complex assembly	-5.95253	< 10 <sup>-5</sup>
GO:0071822	protein complex subunit organization	-5.90784	< 10 <sup>-5</sup>
GO:1902580	single-organism cellular localization	-5.87975	< 10 <sup>-5</sup>
GO:0070727	cellular macromolecule localization	-5.83766	< 10 <sup>-5</sup>
GO:0010941	regulation of cell death	-5.80849	< 10 <sup>-5</sup>
GO:0031399	regulation of protein modification process	-5.80517	< 10 <sup>-5</sup>
GO:0009617	response to bacterium	-5.7918	< 10 <sup>-5</sup>
GO:0006413	translational initiation	-5.75062	< 10 <sup>-5</sup>
GO:0051247	positive regulation of protein metabolic process	-5.73842	< 10 <sup>-5</sup>
GO:0009605	response to external stimulus	-5.73487	< 10 <sup>-5</sup>

**Table S2. AD skin demonstrates enrichment of immune activation pathways. Relates to Figure 5.**

List of top 50 biological process GO terms enriched in AD in a direct comparison of CIP and AD as determined by gene set enrichment analysis (GSEA). Normalized enrichment score (NES) and false discovery rate (FDR) q-value of individual GO terms are provided.

GO Accession Number	Name	NES	FDR q-value
GO:0032990	cell part morphogenesis	3.093461	0.002029
GO:0044782	cilium organization	2.879501	0.002522
GO:0060271	cilium morphogenesis	2.867324	0.002018
GO:0008589	regulation of smoothened signaling pathway	2.766102	0.003024
GO:0016054	organic acid catabolic process	2.669138	0.006637
GO:0046395	carboxylic acid catabolic process	2.666201	0.005615
GO:0051965	positive regulation of synapse assembly	2.584534	0.010122
GO:0016339	calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules	2.545489	0.011865
GO:0033539	fatty acid beta-oxidation using acyl-CoA dehydrogenase	2.528827	0.012158
GO:0010927	cellular component assembly involved in morphogenesis	2.521315	0.011644
GO:0048667	cell morphogenesis involved in neuron differentiation	2.399559	0.028197
GO:0072329	monocarboxylic acid catabolic process	2.391039	0.027353
GO:0007156	homophilic cell adhesion via plasma membrane adhesion molecules	2.374797	0.027991
GO:0097485	neuron projection guidance	2.356602	0.029745
GO:0098742	cell-cell adhesion via plasma-membrane adhesion molecules	2.32599	0.035653
GO:0051298	centrosome duplication	2.27191	0.048845
GO:0009062	fatty acid catabolic process	2.266665	0.047421
GO:0061512	protein localization to cilium	2.250689	0.050193
GO:0030030	cell projection organization	2.228846	0.055343
GO:0003002	regionalization	2.225651	0.053408
GO:0050807	regulation of synapse organization	2.176872	0.069665
GO:0007224	smoothened signaling pathway	2.16341	0.072499
GO:0048812	neuron projection morphogenesis	2.149574	0.076482
GO:0019228	neuronal action potential	2.135246	0.080783
GO:0071236	cellular response to antibiotic	2.118108	0.08638
GO:0021915	neural tube development	2.111597	0.086502
GO:0021522	spinal cord motor neuron differentiation	2.103877	0.087523
GO:0007600	sensory perception	2.094911	0.089596
GO:0007389	pattern specification process	2.093567	0.087319
GO:0050953	sensory perception of light stimulus	2.082521	0.090076
GO:0021510	spinal cord development	2.050129	0.106422
GO:0000732	strand displacement	2.047653	0.104586
GO:0045494	photoreceptor cell maintenance	2.045306	0.103041
GO:0032989	cellular component morphogenesis	2.042259	0.10153
GO:0021515	cell differentiation in spinal cord	2.028853	0.107171
GO:0019748	secondary metabolic process	2.026103	0.10577
GO:1903825	organic acid transmembrane transport	2.017075	0.108687
GO:0035058	nonmotile primary cilium assembly	2.012586	0.108942
GO:0060401	cytosolic calcium ion transport	1.995952	0.117028
GO:0097553	calcium ion transmembrane import into cytosol	1.986171	0.121127
GO:0031023	microtubule organizing center organization	1.977455	0.124149
GO:0007517	muscle organ development	1.97117	0.125907
GO:1902656	calcium ion import into cytosol	1.970663	0.123353
GO:0007098	centrosome cycle	1.96972	0.121292
GO:0086010	membrane depolarization during action potential	1.964156	0.122664
GO:0098534	centriole assembly	1.960917	0.122407
GO:0070509	calcium ion import	1.959427	0.121073
GO:0009953	dorsal/ventral pattern formation	1.955245	0.121612
GO:0097237	cellular response to toxic substance	1.954725	0.119552

**Table S3. CIP skin demonstrates enrichment of transcriptional programs not associated with inflammation. Relates to Figure 5.**

List of top 50 biological process GO terms enriched in CIP in a direct comparison of CIP and AD as determined by gene set enrichment analysis (GSEA). Normalized enrichment score (NES) and false discovery rate (FDR) q-value of individual GO terms are provided.

	Age	Sex	History of AD	History of malignancy	Previously failed treatments						
					Topical steroids	Oral steroids	Additional Immuno-suppression <sup>a</sup>	Gabapentin	Anti-histamines	Anti-depressants	Photo-therapy
<b>Patient 1</b>	79	M	None	None	Yes	Yes	Yes	Yes	Yes	Yes	N/A
<b>Patient 2</b>	50	F	None	None	Yes	Yes	N/A	N/A	Yes	N/A	N/A
<b>Patient 3</b>	60	M	None	None	Yes	Yes	N/A	N/A	Yes	N/A	Yes
<b>Patient 4</b>	79	M	None	Yes	Yes	Yes	Yes	Yes	N/A	Yes	N/A
<b>Patient 5</b>	75	F	None	Yes	Yes	Yes	N/A	N/A	N/A	N/A	Yes

<sup>a</sup> azathioprine or cyclosporine

**Table S4. Characteristics of CIP patients treated with tofacitinib. Relates to Figure 6.**

Demographics and relevant medical history including previously failed treatments of CIP patients given tofacitinib. N/A, not applicable.